Nutra Pharma Corp (OTC:NPHC) has announced that it has submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling its Nyloxin OTC and Nyloxin RX. Nyloxin OTC is an over the counter treatment for moderate to severe chronic pain. Nyloxin Rx is a prescription treatment for severe chronic pain.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
Nutra Pharma Corp is a biopharmaceutical company engaged in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for neurological disorders, cancer, autoimmune and infectious diseases. Its wholly owned subsidiary, ReceptoPharm, Inc. is engaged in the development of technologies to treat neurological diseases such as multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, myasthenia gravis, and to treat viral diseases such as human immunodeficiency virus (HIV), and hepatitis-C. Nutra Pharma’s other wholly owned subsidiary Designer Diagnostics, Inc. markets diagnostic test kits for the rapid identification of infectious human diseases.
Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer
